Clinical Trial
Treatment of Moderate to Severe Lateral Canthal Lines
Study Description
“Treatment of Moderate to Severe Lateral Canthal Lines”
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
Location
Methods
No pharmaceutical medication involved
Patients and healthy individuals accepted
Biological - botulinum toxin
neuromodulator
Biological - Placebo
placebo
Additional Information
Official Study Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Clinical Trial ID
NCT04249687
ParticipAid ID
dR6Z0d
